bezafibrate has been researched along with uric acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastow, MD; Durrington, PN; Ishola, M | 1 |
| Inokuchi, T; Ka, T; Kobayashi, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T | 1 |
| Behar, S; Boyko, V; Brodov, Y; Chouraqui, P; Goldenberg, I | 1 |
| Behar, S; Boyko, V; Brodov, Y; Chouraqui, P | 1 |
| Dohmen, K; Haruno, M; Tanaka, H | 1 |
3 trial(s) available for bezafibrate and uric acid
| Article | Year |
|---|---|
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
Topics: Bezafibrate; Clinical Trials as Topic; Dietary Carbohydrates; Double-Blind Method; Fenofibrate; Fructose; Humans; Lipoproteins; Male; Propionates; Triglycerides; Uric Acid | 1988 |
Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.
Topics: Bezafibrate; Biomarkers; Body Mass Index; Fenofibrate; Gout; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Nephrolithiasis; PPAR alpha; Regression Analysis; Triglycerides; Uric Acid | 2007 |
Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperuricemia; Hypolipidemic Agents; Incidence; Israel; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Triglycerides; Uric Acid | 2010 |
2 other study(ies) available for bezafibrate and uric acid
| Article | Year |
|---|---|
Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Topics: Aged; Analysis of Variance; Bezafibrate; Biomarkers; C-Reactive Protein; Cohort Studies; Confidence Intervals; Coronary Artery Disease; Endpoint Determination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid | 2009 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid | 2013 |